🟢 Tscan Therapeutics is trading 7.9% up in pre-market with no identified catalyst

Tscan Therapeutics is trading at $0.25, up 7.88%, in pre-market; no specific catalyst for the move was identified.

• The latest company filing proposes a 1-for-2 to 1-for-50 reverse split for a November 20 shareholder vote, following Nasdaq’s minimum-bid-price deficiency.
• No specific October 19 news catalyst was found. Major indices were higher, while biotech-sector weakness did not explain the stock’s rise.
• No pre-market volume data was provided, so trading activity cannot be assessed.